Overview

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Status:
Terminated

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal patients with hormone sensitive breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Yale University

Collaborators:

Genentech, Inc.
Novartis

Treatments:

Bevacizumab
Hormones
Letrozole